Zachary Conrad Hartman
Associate Professor in Surgery
My research interests encompass studies of immunity and inflammation in the context of developing and established cancers. These research interests involve studies of inflammation in the genesis and maintenance of specific cancer types (principally breast and ovarian), as well as the impact of inflammation on tumor metastasis and the tumor microenvironment. My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies and development of vaccines to specific oncogenic targets. The major focus of my lab is in uncovering strategies to modulate tumor-derived inflammation and tumor-specific immunity that will translate into clinically efficacious therapies in patients.
Current Appointments & Affiliations
- Associate Professor in Surgery, Surgery, Surgical Sciences, Surgery 2022
- Assistant Professor in Immunology, Immunology, Basic Science Departments 2021
- Associate Professor in Pathology, Pathology, Clinical Science Departments 2022
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2020
Contact Information
- Box 2606 Med Ctr, Durham, NC 27710
- Research Drive, Msrbi Rm 414, Durham, NC 27710
-
zachary.hartman@duke.edu
(919) 613-9110
-
Tumor Immunology and Immunotherapeutics Laboratory
- Background
-
Education, Training, & Certifications
- Postdoctoral Fellow, Md Anderson Cancer Center, University of Texas Medical School, Houston 2010 - 2012
- Postdoctoral Fellow, Duke University 2006 - 2010
- Ph.D., Duke University 2006
-
Previous Appointments & Affiliations
- Associate Professor in Pathology, Pathology, Clinical Science Departments 2021 - 2022
- Associate Professor in Surgery, Surgery, Surgical Sciences, Surgery 2021 - 2022
- Assistant Professor in Pathology, Pathology, Clinical Science Departments 2021
- Assistant Professor in Surgery, Surgery, Surgical Sciences, Surgery 2021
- Assistant Professor of Surgery, Surgery, Surgical Sciences, Surgery 2012 - 2020
- Assistant Professor in Pathology, Pathology, Clinical Science Departments 2018 - 2020
- Instructor, Temporary in the Department of Surgery, Surgery, Surgical Sciences, Surgery 2012
- Recognition
-
In the News
-
MAR 18, 2022 Duke Health News -
OCT 15, 2021 Duke Health News -
NOV 14, 2019 Duke Health News
-
- Research
-
Selected Grants
- Visualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancer awarded by National Institutes of Health 2021 - 2026
- Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory awarded by Department of Defense 2021 - 2025
- Genetic and Genomics Training Grant awarded by National Institutes of Health 2020 - 2025
- Personalized T-cell immunity against metastatic TNBC using MAVS immunostimulation awarded by Susan G Komen for the Cure 2022 - 2025
- Mouse Paint: A massively combinatorial approach for illuminating tumor heterogeneity in True Color awarded by National Institutes of Health 2022 - 2025
- Improving Cardiac Transplant Outcomes Through PD-L1 Overexpression Gene Therapy awarded by American Heart Association 2023 - 2024
- Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers awarded by National Institutes of Health 2019 - 2024
- Viral Oncology Training Grant awarded by National Institutes of Health 1980 - 2024
- Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer awarded by Department of Defense 2020 - 2024
- Investigation of LAMP anti-tumor vaccines awarded by Immunomic Therapeutics, Inc. 2020 - 2023
- Investigating the adaptive immune response to dormant tumor cells awarded by American Cancer Society, Inc. 2020 - 2023
- Detection and Elimination of Oncogenic Signaling Networks in Pre-malignant and Malignant Cells with Magnetic Resonance Imaging awarded by Department of Defense 2012 - 2022
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2022
- A Neoepitope Subunit Vaccine Targeting the Mutated Estrogen Receptor Ligand Binding Domain to Treat and Prevent Endocrine Resistant ER+ Breast Cancer awarded by Department of Defense 2018 - 2022
- Efficacy of replicon-encapsulated lipid nanoparticles for vaccination against breast cancer in vivo awarded by Replicate Bioscience, Inc. 2021 - 2022
- Investigation of stimulating stress response mechanisms to enhance antibody dependent cellular phagocytosis awarded by Bantam Pharmaceutical, LLC 2019 - 2021
- Mechanisms of Action and Resistance to PD-1 Immunotherapies in Breast Cancer awarded by Merck 2017 - 2020
- Study of LAMP Vaccines in HER2+ Breast Cancer awarded by Immunomic Therapeutics, Inc. 2017 - 2020
- Immunotherapeutic Targeting of a Therapy Resistant Oncogenic HER2 Isoform awarded by Susan G. Komen Breast Cancer Foundation 2017 - 2020
- Investigating Adaptive Immune Recognition of Dormant Disseminated Tumor Cells awarded by Fred Hutchinson Cancer Research Center 2017 - 2019
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
-
External Relationships
- Bantam Pharmaceuticals
- Cell Microsystems
- Replicate Biosciences, LLC
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Kaneko, Kensuke, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, et al. “A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity.” Cancers (Basel) 14, no. 23 (November 23, 2022). https://doi.org/10.3390/cancers14235762.Full Text Link to Item
-
Kaneko, Kensuke, Chaitanya R. Acharya, Hiroshi Nagata, Xiao Yang, Zachary Conrad Hartman, Amy Hobeika, Philip F. Hughes, et al. “Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.” J Immunother Cancer 10, no. 9 (September 2022). https://doi.org/10.1136/jitc-2022-004793.Full Text Link to Item
-
Dailey, Gabrielle P., Erika J. Crosby, and Zachary C. Hartman. “Cancer vaccine strategies using self-replicating RNA viral platforms.” Cancer Gene Ther, July 12, 2022, 1–9. https://doi.org/10.1038/s41417-022-00499-6.Full Text Link to Item
-
Tsao, Li-Chung, Erika J. Crosby, Timothy N. Trotter, Junping Wei, Tao Wang, Xiao Yang, Amanda N. Summers, et al. “Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis.” Jci Insight 7, no. 6 (March 22, 2022). https://doi.org/10.1172/jci.insight.155636.Full Text Link to Item
-
Hwang, Bin-Jin, Li-Chung Tsao, Chaitanya R. Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, et al. “Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.” J Immunother Cancer 10, no. 3 (March 2022). https://doi.org/10.1136/jitc-2021-003721.Full Text Link to Item
-
Osada, Takuya, Erika J. Crosby, Kensuke Kaneko, Joshua C. Snyder, Joshua D. Ginzel, Chaitanya R. Acharya, Xiao-Yi Yang, et al. “HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.” Mol Cancer Ther 21, no. 1 (January 2022): 217–26. https://doi.org/10.1158/1535-7163.MCT-21-0334.Full Text Link to Item
-
Hartman, Zachary C. “How can we create precision immunotherapy as standard in breast cancer?” Expert Rev Anticancer Ther 21, no. 11 (November 2021): 1179–81. https://doi.org/10.1080/14737140.2021.1951241.Full Text Link to Item
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.” Mol Cancer Res 19, no. 10 (October 2021): 1699–1711. https://doi.org/10.1158/1541-7786.MCR-21-0215.Full Text Link to Item
-
Tsao, Li-Chung, Jeremy Force, and Zachary C. Hartman. “Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.” Cancer Res 81, no. 18 (September 15, 2021): 4641–51. https://doi.org/10.1158/0008-5472.CAN-21-1109.Full Text Link to Item
-
Werner, Lauryn R., Katelin A. Gibson, Merit L. Goodman, Dominika E. Helm, Katherine R. Walter, Sean M. Holloran, Gloria M. Trinca, et al. “Progesterone promotes immunomodulation and tumor development in the murine mammary gland.” J Immunother Cancer 9, no. 5 (May 2021). https://doi.org/10.1136/jitc-2020-001710.Full Text Link to Item
-
Crosby, Erika J., H Kim Lyerly, and Zachary C. Hartman. “Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors.” Oncotarget 12, no. 1 (January 5, 2021): 1–3. https://doi.org/10.18632/oncotarget.27861.Full Text Link to Item
-
Crosby, Erika J., Amy C. Hobeika, Donna Niedzwiecki, Christel Rushing, David Hsu, Peter Berglund, Jonathan Smith, et al. “Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.” J Immunother Cancer 8, no. 2 (November 2020). https://doi.org/10.1136/jitc-2020-001662.Full Text Link to Item
-
Crosby, Erika J., Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, et al. “Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.” Clin Cancer Res 26, no. 17 (September 1, 2020): 4670–81. https://doi.org/10.1158/1078-0432.CCR-20-0389.Full Text Link to Item
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils.” Cancer Res 80, no. 15 (August 1, 2020): 3088–3100. https://doi.org/10.1158/0008-5472.CAN-18-3825.Full Text Link to Item
-
Chen, Alan Chen, Renhuan Xu, Tao Wang, Junping Wei, Xiao-Yi Yang, Cong-Xiao Liu, Gangjun Lei, Herbert Kim Lyerly, Teri Heiland, and Zachary Conrad Hartman. “HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression.” J Immunother Cancer 8, no. 1 (June 2020). https://doi.org/10.1136/jitc-2019-000258.Full Text Link to Item
-
Tsao, Li-Chung, Erika J. Crosby, Timothy N. Trotter, Pankaj Agarwal, Bin-Jin Hwang, Chaitanya Acharya, Casey W. Shuptrine, et al. “CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.” Jci Insight 4, no. 24 (December 19, 2019). https://doi.org/10.1172/jci.insight.131882.Full Text Link to Item
-
Kula, Tomasz, Mohammad H. Dezfulian, Charlotte I. Wang, Nouran S. Abdelfattah, Zachary C. Hartman, Kai W. Wucherpfennig, Herbert Kim Lyerly, and Stephen J. Elledge. “T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.” Cell 178, no. 4 (August 8, 2019): 1016-1028.e13. https://doi.org/10.1016/j.cell.2019.07.009.Full Text Link to Item
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.Full Text Open Access Copy Link to Item
-
Lyerly, H Kim, Takuya Osada, and Zachary C. Hartman. “Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy.” Clin Cancer Res 25, no. 1 (January 1, 2019): 9–11. https://doi.org/10.1158/1078-0432.CCR-18-2819.Full Text Link to Item
-
Osada, Takuya, Zachary C. Hartman, Junping Wei, Gangjun Lei, Amy C. Hobeika, William R. Gwin, Marcio A. Diniz, et al. “Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.” Breast Cancer Res 20, no. 1 (August 9, 2018): 90. https://doi.org/10.1186/s13058-018-1023-x.Full Text Link to Item
-
Crosby, Erika J., Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, et al. “Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.” Oncoimmunology 7, no. 5 (2018): e1421891. https://doi.org/10.1080/2162402X.2017.1421891.Full Text Link to Item
-
Osada, Takuya, Kensuke Kaneko, William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, and H Kim Lyerly. “In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7531–42. https://doi.org/10.1158/1078-0432.CCR-17-1453.Full Text Link to Item
-
Shuptrine, Casey W., Reham Ajina, Elana J. Fertig, Sandra A. Jablonski, H. Kim Lyerly, Zachary C. Hartman, and Louis M. Weiner. “An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.” Cancer Immunol Immunother 66, no. 12 (December 2017): 1529–44. https://doi.org/10.1007/s00262-017-2047-2.Full Text Link to Item
-
Osada, Takuya, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, et al. “Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.” Oncoimmunology 6, no. 6 (2017): e1315495. https://doi.org/10.1080/2162402X.2017.1315495.Full Text Link to Item
-
Ren, Jun, William R. Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, et al. “Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.” Oncoimmunology 6, no. 4 (2017): e1264563. https://doi.org/10.1080/2162402X.2016.1264563.Full Text Link to Item
-
Turpin, J., C. Ling, E. J. Crosby, Z. C. Hartman, A. M. Simond, L. A. Chodosh, J. P. Rennhack, et al. “The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.” Oncogene 35, no. 47 (November 24, 2016): 6053–64. https://doi.org/10.1038/onc.2016.129.Full Text Link to Item
-
Mazumdar, Abhijit, Graham M. Poage, Jonathan Shepherd, Anna Tsimelzon, Zachary C. Hartman, Petra Den Hollander, Jamal Hill, et al. “Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.” Breast Cancer Res Treat 158, no. 3 (August 2016): 441–54. https://doi.org/10.1007/s10549-016-3892-y.Full Text Link to Item
-
Zhao, Jing, Dekuang Zhao, Graham M. Poage, Abhijit Mazumdar, Yun Zhang, Jamal L. Hill, Zachary C. Hartman, Michelle I. Savage, Gordon B. Mills, and Powel H. Brown. “Death-associated protein kinase 1 promotes growth of p53-mutant cancers.” J Clin Invest 125, no. 7 (July 1, 2015): 2707–20. https://doi.org/10.1172/JCI70805.Full Text Link to Item
-
Osada, Takuya, Koji Nagaoka, Masashi Takahara, Xiao Yi Yang, Cong-Xiao Liu, Hongtao Guo, Kingshuk Roy Choudhury, et al. “Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.” J Immunother 38, no. 4 (May 2015): 155–64. https://doi.org/10.1097/CJI.0000000000000075.Full Text Link to Item
-
Barrott, Jared J., Philip F. Hughes, Takuya Osada, Xiao-Yi Yang, Zachary C. Hartman, David R. Loiselle, Neil L. Spector, et al. “Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.” Chem Biol 20, no. 9 (September 19, 2013): 1187–97. https://doi.org/10.1016/j.chembiol.2013.08.004.Full Text Link to Item
-
Poage, Graham M., Zachary C. Hartman, and Powel H. Brown. “Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy.” Cell Cycle 12, no. 17 (September 1, 2013): 2705–6. https://doi.org/10.4161/cc.25871.Full Text Link to Item
-
Hartman, Zachary C., Graham M. Poage, Petra den Hollander, Anna Tsimelzon, Jamal Hill, Nattapon Panupinthu, Yun Zhang, et al. “Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.” Cancer Res 73, no. 11 (June 1, 2013): 3470–80. https://doi.org/10.1158/0008-5472.CAN-12-4524-T.Full Text Link to Item
-
Kessler, J. D., K. T. Kahle, T. Sun, K. L. Meerbrey, M. R. Schlabach, E. M. Schmitt, S. O. Skinner, et al. “A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.” Science 335, no. 6066 (January 20, 2012): 348–53. https://doi.org/10.1126/science.1212728.Full Text
-
Hartman, Zachary C., Junping Wei, Oliver K. Glass, Hongtao Guo, Gangjun Lei, Xiao-Yi Yang, Takuya Osada, et al. “Increasing vaccine potency through exosome antigen targeting.” Vaccine 29, no. 50 (November 21, 2011): 9361–67. https://doi.org/10.1016/j.vaccine.2011.09.133.Full Text Link to Item
-
Xia, Wenle, Zuguo Liu, Rongrong Zong, Leihua Liu, Sumin Zhao, Sarah S. Bacus, Yubin Mao, et al. “Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.” Mol Cancer Ther 10, no. 8 (August 2011): 1367–74. https://doi.org/10.1158/1535-7163.MCT-10-0991.Full Text Link to Item
-
Hartman, Zachary C., Xiao-Yi Yang, Oliver Glass, Gangjun Lei, Takuya Osada, Sandeep S. Dave, Michael A. Morse, Timothy M. Clay, and Herbert K. Lyerly. “HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.” Cancer Res 71, no. 13 (July 1, 2011): 4380–91. https://doi.org/10.1158/0008-5472.CAN-11-0308.Full Text Link to Item
-
Clay, Timothy M., Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, and H Kim Lyerly. “Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.” Immunol Res 49, no. 1–3 (April 2011): 235–47. https://doi.org/10.1007/s12026-010-8186-6.Full Text Link to Item
-
Hartman, Zachary C., Takuya Osada, Oliver Glass, Xiao Y. Yang, Gang-Jun Lei, H Kim Lyerly, and Timothy M. Clay. “Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.” Cancer Res 70, no. 18 (September 15, 2010): 7209–20. https://doi.org/10.1158/0008-5472.CAN-10-0905.Full Text Link to Item
-
Seregin, Sergey S., Yasser A. Aldhamen, Daniel M. Appledorn, Zachary C. Hartman, Nathaniel J. Schuldt, Jeannine Scott, Sarah Godbehere, Haixiang Jiang, Michael M. Frank, and Andrea Amalfitano. “Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.” Blood 116, no. 10 (September 9, 2010): 1669–77. https://doi.org/10.1182/blood-2010-03-276949.Full Text Link to Item
-
Gabitzsch, Elizabeth S., Younong Xu, Joseph P. Balint, Zachary C. Hartman, H Kim Lyerly, and Frank R. Jones. “Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.” Cancer Immunol Immunother 59, no. 7 (July 2010): 1131–35. https://doi.org/10.1007/s00262-010-0847-8.Full Text Link to Item
-
Morse, Michael A., Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei, William T. Barry, et al. “Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.” Int J Cancer 126, no. 12 (June 15, 2010): 2893–2903. https://doi.org/10.1002/ijc.24995.Full Text Link to Item
-
Hartman, Zachary C., Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, et al. “An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.” Clin Cancer Res 16, no. 5 (March 1, 2010): 1466–77. https://doi.org/10.1158/1078-0432.CCR-09-2549.Full Text Link to Item
-
Seregin, Sergey S., Zachary C. Hartman, Daniel M. Appledorn, Sarah Godbehere, Haixiang Jiang, Michael M. Frank, and Andrea Amalfitano. “Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.” J Innate Immun 2, no. 4 (2010): 353–59. https://doi.org/10.1159/000284368.Full Text Link to Item
-
Osada, T., X. Y. Yang, Z. C. Hartman, O. Glass, B. L. Hodges, D. Niedzwiecki, M. A. Morse, H. K. Lyerly, A. Amalfitano, and T. M. Clay. “Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.” Cancer Gene Ther 16, no. 9 (September 2009): 673–82. https://doi.org/10.1038/cgt.2009.17.Full Text Link to Item
-
Osada, Takuya, Christopher Y. Woo, Matthew McKinney, Xiao Yi Yang, Gangjun Lei, Heather G. Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.” Clin Cancer Res 15, no. 8 (April 15, 2009): 2789–96. https://doi.org/10.1158/1078-0432.CCR-08-2589.Full Text Link to Item
-
Cohen, Todd J., Tomasa Barrientos, Zachary C. Hartman, Sean M. Garvey, Gregory A. Cox, and Tso-Pang Yao. “The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.” Faseb J 23, no. 1 (January 2009): 99–106. https://doi.org/10.1096/fj.08-115931.Full Text Link to Item
-
Hartman, Zachary C., Daniel M. Appledorn, Delila Serra, Oliver Glass, Todd B. Mendelson, Timothy M. Clay, and Andrea Amalfitano. “Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.” Virology 374, no. 2 (May 10, 2008): 453–67. https://doi.org/10.1016/j.virol.2008.01.017.Full Text Link to Item
-
Hartman, Zachary C., Daniel M. Appledorn, and Andrea Amalfitano. “Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.” Virus Res 132, no. 1–2 (March 2008): 1–14. https://doi.org/10.1016/j.virusres.2007.10.005.Full Text Link to Item
-
Hartman, Zachary C., Esther P. Black, and Andrea Amalfitano. “Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells.” Virology 358, no. 2 (February 20, 2007): 357–72. https://doi.org/10.1016/j.virol.2006.08.041.Full Text Link to Item
-
Hartman, Zachary C., Anne Kiang, Ruth S. Everett, Delila Serra, Xiao Y. Yang, Timothy M. Clay, and Andrea Amalfitano. “Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.” J Virol 81, no. 4 (February 2007): 1796–1812. https://doi.org/10.1128/JVI.01936-06.Full Text Link to Item
-
Kiang, Anne, Zachary C. Hartman, Ruth S. Everett, Delila Serra, Haixiang Jiang, Michael M. Frank, and Andrea Amalfitano. “Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.” Mol Ther 14, no. 4 (October 2006): 588–98. https://doi.org/10.1016/j.ymthe.2006.03.024.Full Text Link to Item
-
Kiang, Anne, Zachary C. Hartman, Shaoxi Liao, Fang Xu, Delila Serra, Donna J. Palmer, Philip Ng, and Andrea Amalfitano. “Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.” Mol Ther 13, no. 1 (January 2006): 127–34. https://doi.org/10.1016/j.ymthe.2005.08.006.Full Text Link to Item
-
-
Conference Papers
-
Crosby, Erika J., Chaitanya Acharya, Christopher Rabiola, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Jonathan Shepherd, et al. “Abstract 904: Stimulation and expansion of oncogene-reactive tumor infiltrating T cells through combined Ad-HER2Δ16 vaccination and anti-PD1 enable anti-tumor responses against established HER2 BC.” In Cancer Research, 80:904–904. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.am2020-904.Full Text
-
Hwang, Bin-Jin, Li-Chung Tsao, Gabriel DeLeon, Junping Wei, Xiao-Yi Yang, Gangjun Lei, Tao Wang, Michael M. Morse, Herbert Kim Lyerly, and Zachary Conrad Hartman. “Overexpression of MAVS stimulates antitumor immunity and significantly reduces tumor growth of immune-insensitive colorectal cancer in vivo.” In Cancer Immunology Research, 8:24–25. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Hwang, Bin-Jin, Li-Chung Tsao, Gabriel DeLeon, Junping Wei, Xiao-Yi Yang, Gangjun Lei, Tao Wang, Michael M. Morse, Herbert Kim Lyerly, and Zachary Conrad Hartman. “PR2 Overexpression of MAVS stimulates antitumor immunity and significantly reduces tumor growth of immune-insensitive colorectal cancer in vivo.” In Cancer Immunology Research, 8:53–54. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Trotter, Timothy N., Cong-Xiao Liu, Tao Wang, H Kim Lyerly, and Zachary C. Hartman. “Dormant breast tumor cells avoid the adaptive immune system through regulation of the immune and tumor microenvironment.” In Cancer Immunology Research, 8:139–40. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Tsao, Li-Chung, Jun-Ping Wei, Gang-jun Lei, Tao Wang, Xiao-Yi Yang, Cong-Xiao Liu, H Kim Lyerly, and Zachary C. Hartman. “Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade.” In Immunology. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.sabcs18-3955.Full Text
-
Crosby, E. J., W. R. Gwin, S. Chang, H. T. Maecker, V. Lubkov, J. C. Snyder, G. Broadwater, et al. “Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients.” In Cancer Research, Vol. 79. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.sabcs18-p2-09-16.Full Text
-
Crosby, Erika J., Gangjun Lei, Junping Wei, Xiao Yi Yang, Tao Wang, Cong-Xiao Liu, H Kim Lyerly, and Zachary C. Hartman. “Abstract A22: Augmentation of a novel adenoviral vaccine strategy by checkpoint inhibitors.” In Cancer Immunology Research, 6:A22–A22. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/2326-6074.tumimm17-a22.Full Text
-
Crosby, Erika J., Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, H Kim Lyerly, and Zachary C. Hartman. “Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression.” In Cancer Immunology Research, 5:A38–A38. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/2326-6074.tumimm16-a38.Full Text
-
Hartman, Z. C., E. J. Crosby, J. -. P. Wei, X. -. Y. Yang, G. -. J. Lei, T. Wang, C. -. X. Liu, P. Agarwal, M. S. Morse, and H. K. Lyerly. “Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer.” In Cancer Research, Vol. 77. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.sabcs16-p2-04-27.Full Text
-
Kessler, Jessica D., Kristopher T. Kahle, Tingting Sun, Kristen L. Meerbrey, Michael R. Schlabach, Earlene M. Schmitt, Samuel O. Skinner, et al. “A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.” In Cancer Research, Vol. 72, 2012. https://doi.org/10.1158/1538-7445.AM2012-3091.Full Text Link to Item
-
Seregin, Sergey S., Zachary C. Hartman, Daniel M. Appledorn, Yasser A. Aldhamen, Nathaniel J. Schuldt, Mathew Bujold, Sarah Godbehere, and Andrea Amalfitano. “Improved Safety Profile of Novel Adenovirus Based Vectors "Capsid-displaying" Complement Inhibitors: Increased Potential for Cardiovascular Gene Transfer Applications.” In Circulation, 120:S899–900. LIPPINCOTT WILLIAMS & WILKINS, 2009.Link to Item
-
Woo, Christopher Y., Takuya Osada, Xiao Yi Yang, Gangjun Lei, Matthew McKinney, Heather Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific immunity using a WT1-expressing adenovirus vaccine.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Osada, Takuya, Heather Labreche, Zachery C. Hartman, Delila Serra, Michael A. Morse, H Kim Lyerly, Andrea Amalfitano, and Timothy M. Clay. “Replication-competent packaging-deficient [E1+, 100k-] adenoviral vector-transduced dendritic cells can efficiently induce antigen-specific immune responses.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Hartman, Zachary C., Todd Mendelson, and Andrea Amalfitano. “19. A New, Plasmid-Based Adenoviral Vectoring System Derived from the Highly Immunogenic, Human Ad4 Strain.” In Molecular Therapy, 13:S8–S8. Elsevier BV, 2006. https://doi.org/10.1016/j.ymthe.2006.08.030.Full Text
-
-
- Teaching & Mentoring
-
Recent Courses
- PATHOL 293: Research Independent Study 2023
- UPGEN 716S: Genetics Student Research 2023
- PATHOL 293: Research Independent Study 2022
- PATHOL 793: Research Independent Study 2022
- UPGEN 716S: Genetics Student Research 2022
- PATHOL 293: Research Independent Study 2021
- PATHOL 793: Research Independent Study 2021
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
